The EMPA-REG study: What has it told us? A diabetologist's perspective

Journal of Diabetes and its Complications

Volumn 30, Issue 1, 2016, Pages 1-2

  Defronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC PATIENT; DRUG MECHANISM; EDITORIAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK REDUCTION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; COMPLICATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; METABOLISM; RISK FACTOR;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MEMBRANE TRANSPORT MODULATORS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84951814585     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.10.013     Document Type: Editorial

References (16)

1. M. Abdul-Ghani, L. Norton, and R.A. DeFronzo Role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes Endocrine Reviews 32 2011 515 531
2. D.Z. Cherney, B.A. Perkins, N. Soleymanlou, R. Har, N. Fagan, O.E. Johansen The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus Cardiovascular Diabetology 29 13 2014 28
3. G.D. Clarke, M. Molina-Wilkins, S. Martinez, A. Merovci, J.R. Kincade, and C. Solis-Herrera R.A. DeFronzo Improved left ventricular diastolic function (LVDF) following pioglitazone therapy is strongly related to increased myocardial insulin sensitivity Diabetes 63 Suppl. 1 2014 A298
4. J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, and I.K. Moules PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial Lancet 366 2005 1279 1289
5. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, and P.D. Reaven VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes NEJM 360 2009 129 139
6. R. Eldor, R.A. DeFronzo, and M. Abdul-Ghani In vivo actions of peroxisome proliferator-activated receptors: Glycemic control, insulin sensitivity and insulin secretion Diabetes Care 36 Suppl. 2 2013 S1627 S1674
7. P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, and O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes The New England Journal of Medicine 348 5 2003 383 393
8. H.C. Gerstein, M.E. Miller, R.P. Byington, D.C. Goff Jr., J.T. Bigger, and J.B. Buse W.T. Friedewald Effects of intensive glucose lowering in type 2 diabetes NEJM 358 2008 2545 2559
9. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A. Neil 10-year follow-up of intensive glucose control in type 2 diabetes NEJM 359 2008 1577 1589
10. A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, and M. Woodward F. Travert Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes NEJM 358 2008 2560 2572
11. A.L. Peters, E.O. Buschur, J.B. Buse, P. Cohan, J.C. Diner, and I.B. Hirsch Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition Diabetes Care 38 2015 1687 1693
12. R.E.J. Ryder, and R.A. DeFronzo Rehabilitation of pioglitazone The British Journal of Diabetes & Vascular Disease 15 2015 46 49
13. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
14. B. Williams, P.S. Lacy, S.M. Thom, K. Cruickshank, A. Stanton, and D. Collier CAFE Steering Committee and Writing Committee Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study Circulation 113 2006 1213 1225
15. S. Yusuf, S. Hawken, S. Ounpuu, T. Dans, A. Avezum, and F. Lanas INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study Lancet 364 9438 2004 937 952
16. B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, and S. Hantel EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes NEJM 2015 10.1056/NEJMoa1504720 (Epub ahead of print)